Clovis Oncology (Clovis Oncology) EPS (Basic) : $-1.82 (TTM As of Sep. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology EPS (Basic)?

Clovis Oncology's basic earnings per share (Basic EPS) for the three months ended in Sep. 2022 was $-0.39. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.82.

Clovis Oncology's EPS (Diluted) for the three months ended in Sep. 2022 was $-0.39. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.82.

Clovis Oncology's EPS without NRI for the three months ended in Sep. 2022 was $-0.39. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2022 was -1.82.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Clovis Oncology EPS (Basic) Historical Data

The historical data trend for Clovis Oncology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology EPS (Basic) Chart

Clovis Oncology Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Basic)

Get a 7-Day Free Trial

-7.36

-7.07

-7.43

-4.38

-2.29

Clovis Oncology Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EPS (Basic)	Get a 7-Day Free Trial															-0.56	-0.49	-0.44	-0.50	-0.39

Clovis Oncology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Clovis Oncology's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-264.524	-	0)	/	115.528
	=	-2.29

Clovis Oncology's Basic EPS for the quarter that ended in Sep. 2022 is calculated as

Basic EPS (Q: Sep. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-56.014	-	0)	/	144.625
	=	-0.39

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82

Clovis Oncology (OTCPK:CLVSQ) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Clovis Oncology EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Clovis Oncology (Clovis Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301

Website

https://www.clovisoncology.com

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.

Executives

Thomas C. Harding	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read	officer: See Remarks	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl	officer: See remarks	5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov	director	1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair	director	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy	director, officer: President and CEO	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen	director	TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair	director	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein	director	428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham	director	AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104